Table 2.
Spearman rank correlations between healthy controls (HC) and Combined groups (CG), each comprising 24 matched subjects and between the individual PA and TX subgroups
| Spearman rank correlations | P for CG vs. HC | P for PA vs. HC | P for TX vs. HC | P for PA vs. TX | Correlation with QLQ-CIPN20 score |
|---|---|---|---|---|---|
| Age (years) | 0.87 | 0.56 | 0.41 | 0.47 | – |
| Female/Male sex | 0.50 | 0.45 | 0.55 | 0.10 | – |
| Duration since completed chemotherapy (months) | – | – | – | 0.98 | – |
| BMI (kg/m2) | 0.63 | 0.27 | 0.33 | 0.55 | – |
| Systolic blood pressure (mm Hg) | 0.10 | 0.09 | 0.21 | 0.33 | – |
| Diastolic blood pressure (mm Hg) | 0.09 | 0.07 | 0.12 | 0.58 | – |
| Neuropathy disability score (NDS) | – | – | – | 0.06 | 0.10 |
| LDIflare (cm2) | <0.0001 | <0.0001 | 0.005 | 0.007 | <0.0001* |
| Large fibre neuronal parameters | |||||
| Vibration perception threshold (volts) | 0.002 | 0.019 | 0.020 | 0.11 | 0.67* |
| Sural nerve amplitude potential (SNAP – μV) | 0.058 | 0.43 | 0.19 | 0.29 | 0.33* |
| Sural nerve conduction velocity (SNCV – m/sec) | 0.054 | 0.067 | 0.45 | 0.25 | 0.42* |
| QLQ-CIPN20 score | – | – | – | <0.0001 | – |
PA, Platinum analogues; TX, Taxanes; N, number of patients; BMI, body mass index; LDIFLARE, laser Doppler imager flare; EORTC QLQ-CIPN20, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-induced Peripheral Neuropathy 20 module. Significance = P < 0.05 and where significant are shown in bold.
*
As Combined group (CG).